Yahoo Poland Wyszukiwanie w Internecie

Search results

  1. 15 wrz 2022 · Example of an LV apical mural (laminar) thrombus (red arrows) seen on gadolinium-enhanced CMR. Note the adjacent white appearing areas indicating infarcted myocardium. CMR indicates cardiac magnetic resonance; and LV, left ventricular.

    • View EPUB

      PK u!3Yoa«, mimetypeapplication/epub+zipPK u!3Y...

    • Linda S. Williams

      Sleep apnea is associated with increased risk for mortality,...

    • PDF/Epub

      PK ! Yoa«, mimetypeapplication/epub+zipPK ! Y...

    • Trial

      Background—The Randomized Evaluation of Long-term...

  2. These embolic complications could occur at any time under antithrombotic therapy, as a consequence of thrombus fragmentation, quick thrombus regression, or on the contrary, persistence of the thrombus.

  3. 4 lip 2023 · It is vital to treat mural thrombi as this can lower the risk of stroke, myocardial infarction, and pulmonary embolism. There are no standardized guidelines for the treatment of mural thrombi. The type of treatment depends on the location of thrombi, patient symptoms, and urgency of the situation.

  4. 5 mar 2024 · Left ventricular (LV) thrombus may develop after acute myocardial infarction (MI) and occurs most often with a large, anterior ST-elevation MI (STEMI). However, the use of reperfusion therapies, including percutaneous coronary intervention and fibrinolysis, has significantly reduced the risk.

  5. Etiology and Treatment of LV Thrombus. Cumulative etiologies (A) and long-term anticoagulants (B) selected for treatment of left ventricular (LV) thrombus. In-hospital mortality was 7.8%. An additional 7.8% were not initiated on long-term anticoagulation due to medical contraindications.

  6. The most likely explanations for a mural thrombus in the LV are severe LV dysfunction and/or recent anterior wall MI. Echocardiography is the primary modality to detect LVT.

  7. 7 kwi 2020 · Results: The authors identified 159 patients with confirmed LV thrombus. These patients were treated with vitamin K antagonists (48.4%), parenteral heparin (27.7%), or direct oral anticoagulants (22.6%). Antiplatelet therapy was used in 67.9% of cases.

  1. Ludzie szukają również